Jefferies Group LLC reaffirmed their buy rating on shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) in a research note issued to investors on Thursday morning. Jefferies Group LLC currently has a $18.00 target price on the biopharmaceutical company’s stock.

Several other equities analysts have also recently weighed in on SGMO. ValuEngine upgraded shares of Sangamo Therapeutics from a sell rating to a hold rating in a research note on Friday, August 11th. Piper Jaffray Companies set a $8.00 price objective on shares of Sangamo Therapeutics and gave the stock a hold rating in a research note on Thursday, August 10th. BidaskClub cut shares of Sangamo Therapeutics from a hold rating to a sell rating in a research note on Saturday, August 5th. Zacks Investment Research upgraded shares of Sangamo Therapeutics from a hold rating to a buy rating and set a $12.00 price objective on the stock in a research note on Friday, August 18th. Finally, Wells Fargo & Company reissued an outperform rating and issued a $30.00 target price (up from $20.00) on shares of Sangamo Therapeutics in a report on Tuesday, September 5th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the stock. The company currently has an average rating of Hold and an average target price of $14.40.

Sangamo Therapeutics (NASDAQ SGMO) opened at 14.15 on Thursday. Sangamo Therapeutics has a 1-year low of $2.65 and a 1-year high of $15.05. The stock’s market cap is $1.18 billion. The stock has a 50 day moving average of $11.10 and a 200 day moving average of $7.61.

Sangamo Therapeutics (NASDAQ:SGMO) last issued its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.23) by $0.06. Sangamo Therapeutics had a negative net margin of 246.39% and a negative return on equity of 38.49%. The firm had revenue of $8.30 million for the quarter, compared to analysts’ expectations of $5.82 million. During the same quarter in the prior year, the business earned ($0.38) EPS. The business’s quarterly revenue was up 124.3% on a year-over-year basis. Equities analysts anticipate that Sangamo Therapeutics will post ($0.82) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This piece of content was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another site, it was stolen and republished in violation of U.S. and international copyright legislation. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/09/18/sangamo-therapeutics-inc-sgmo-earns-buy-rating-from-jefferies-group-llc.html.

In related news, VP Curt A. Herberts III sold 15,000 shares of the stock in a transaction that occurred on Friday, September 1st. The shares were sold at an average price of $15.00, for a total value of $225,000.00. Following the completion of the sale, the vice president now directly owns 15,833 shares of the company’s stock, valued at approximately $237,495. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Curt A. Herberts III sold 11,474 shares of the stock in a transaction that occurred on Monday, August 14th. The stock was sold at an average price of $10.44, for a total transaction of $119,788.56. Following the completion of the sale, the vice president now directly owns 23,991 shares of the company’s stock, valued at $250,466.04. The disclosure for this sale can be found here. Insiders sold a total of 41,474 shares of company stock valued at $494,789 over the last three months. 8.10% of the stock is currently owned by insiders.

A number of institutional investors have recently added to or reduced their stakes in SGMO. Blair William & Co. IL increased its holdings in Sangamo Therapeutics by 4.3% in the 2nd quarter. Blair William & Co. IL now owns 12,100 shares of the biopharmaceutical company’s stock worth $106,000 after acquiring an additional 500 shares in the last quarter. Aperio Group LLC purchased a new stake in Sangamo Therapeutics during the 2nd quarter valued at approximately $108,000. Principal Financial Group Inc. grew its holdings in Sangamo Therapeutics by 6.8% during the 2nd quarter. Principal Financial Group Inc. now owns 12,978 shares of the biopharmaceutical company’s stock valued at $114,000 after buying an additional 832 shares in the last quarter. Virtu KCG Holdings LLC purchased a new stake in Sangamo Therapeutics during the 2nd quarter valued at approximately $124,000. Finally, Fox Run Management L.L.C. purchased a new stake in Sangamo Therapeutics during the 2nd quarter valued at approximately $126,000. 63.43% of the stock is owned by institutional investors.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.

Analyst Recommendations for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Stock Ratings for Sangamo Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics Inc. and related stocks with our FREE daily email newsletter.